TScan Reprioritizes Around In Vivo TCR-T

Company: TScan Therapeutics · Event: 75% Workforce Reduction + Strategic Pivot · New Focus: In-Vivo TCR-T (PRAME, MAGE-A4) · Paused: Phase III ALLOHA-2 (TSC-101) Enrollment · Date: September 2, 2026 Summary TScan is cutting approximately 75% of its workforce, eliminating internal manufacturing and pausing further…